UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) August 29, 2005
Advaxis,
Inc.
|
(Exact
name of registrant as specified in its
charter)
|
Colorado
|
00028489
|
84-1521955
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
212
Carnegie Center #206, Princeton, New Jersey
|
08546
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (609)
895-7150
|
(Former
name or former address, if changed since last
report.)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01. Other
Events
On
August
29, 2005, the Registrant announced that it successfully completed its
pre-clinical toxicology studies of Lovaxin C, its Listeria Cancer Vaccine,
for
treatment of cervical, head and neck cancers. The results from these studies
complete the toxicology package necessary for the initiation of its Phase
I/II
study in cervical cancer patients. See Registrant’s press release attached
hereto as Exhibit 99.1.
Item
9.01. Financial
Statements and Exhibits
a) Not
applicable.
b) Not
applicable.
c) Exhibits
99.1 Press
Release, dated August 29, 2005.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August
31, 2005 |
|
|
|
ADVAXIS,
INC. |
|
|
|
|
By: |
/s/ J.
Todd Derbin |
|
Name: J.
Todd Derbin |
|
Title:
President and Chief Executive
Officer |